Corvus reports symptom improvement in three ALPS patients in Phase 2 soquelitinib trial

• Corvus Pharmaceuticals will present Phase 2 soquelitinib results in autoimmune lymphoproliferative syndrome at the American Society of Hematology meeting December 14, 2026.
• Three patients completed one year of treatment as of August 3, 2026, reporting improvement in disease-related symptoms.
• Treatment was well tolerated, with no severe adverse events or therapy interruptions.
• All three patients discontinued background medications, including steroids; the rare genetic disorder has no cure or approved treatment.
• The findings support continued enrollment, with plans to explore longer treatment and include younger pediatric patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corvus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040901PRIMZONEFULLFEED9869705) on November 04, 2026, and is solely responsible for the information contained therein.